It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objectives
Blau syndrome (BS) is a rare autoinflammatory disease characterized by a clinical triad of uveitis, dermatitis and arthritis. The aim of our study was to summarize organ involvement, predict disease prognosis and evaluate treatment response.
Methods
Clinical data of 47 Chinese children who were diagnosed with Blau syndrome in Beijing Children’s hospital, Capital Medical University was retrospectively analyzed. Direct sequencing of NOD2 gene was performed by sanger sequencing. Data were analyzed through SPSS 21.0. A Bayesian network was constructed to integrate prediction algorithms of genetic mutations and clinical manifestations, exploring the complex relationship between genotype and phenotype through R (Version 4.4.1, R Core Development Team). P value < 0.05 was significant.
Results
The 47 patients included 26 males and 21 females. Median age of disease onset was 13.64 months, ranging from 1 to 51 months. At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%. Nearly 30% patients (14 patients) presented with characteristic triad. Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively. Inflammatory indices (e.g., erythrocyte sedimentation rate and C reactive protein) were above normal range. Twelve different NOD2 mutations were identified. R334Q was associated with arthritis, rash, uveitis and fever, whereas R334W was associated with arthritis, rash and fever. Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate and 42.6% patients (20 patients) were treated with tumor necrosis factor inhibitors. At the most recent follow-up visit, 34 patients (72.3%) achieved disease control. Patients treated with TNF-α inhibitors had a higher remission rate.
Conclusions
Clinical manifestations of Blau syndrome in this study were various. TNF-α inhibitors were effective in inducing remission rate of Blau syndrome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer